ESTRO 2024 - Abstract Book

S2322

Clinical - Urology

ESTRO 2024

Material/Methods:

Patients affected by oligometastatic CRPC (

Results:

One hundred fifty-seven patients were enrolled in ARTO trial. At last follow up (August 2023), 77 patients progressed after AAP treatment (23 vs 54 in the experimental vs control arm, respectively). Of these, 14 received best supportive care and were excluded from the analysis, 23 underwent SBRT on oligo-progressive metastatic sites (17 and 6 originally randomized to the experimental vs control arm, respectively), 40 were treated with second line systemic treatment. A second progression event was detected in 14 patients. Median PFS1+PFS 2 was 28 months (95% CI 25-34) and 23 months (95% CI 18-32) for patients undergoing SBRT vs second line treatment, respectively (HR 1.09, 95% CI 0.29-4.12, p-value 0.898).

Abiraterone

plus

Abiraterone

plus

Characteristic

prednisone (n=82)

p

prednisone + SBRT (n=75)

Age, years, median (IQR)

74 (68-79)

74 (68-79)

.61

ISUP

grade,

No.

(%)

3

15

(18.3)

13

(17.3)

.87

>3

67 (81.7)

62 (82.7)

Lesion,

No.

(%)

1 >1

25

(30.5)

34

(45.4)

.05

57 (69.5)

41 (54.6)

Metastatic

sites,

No.

(%)

Nodal

only

44

(53.6)

33

(44)

.22

Bone

38 (46.4)

42 (56)

Staging,

No.

(%)

Conventional Choline PSMA/Fluciclovine

11

(13.4)

4

(5.3)

.12

54

(65.9)

48

(64)

17 (20.7)

23 (30.7)

Baseline PSA, median (IQR)

3.42 (1.46-9.35)

3.42 (1.47-9.36)

.14

Conclusion: